Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TriSalus Life Sciences, Inc. amended loan of $544,000 and $400,000 with MedTech Acquisition Sponsor LLC.
- Instrument
- loan
- Principal
- $544,000 and $400,000
- Counterparty
- MedTech Acquisition Sponsor LLC
- Event
- amendment
Exact text from the filing
disclosed, on December 30, 2021 and January 28, 2022, MedTech Acquisition Corporation (the “Company”) issued an unsecured promissory note in the principal amount of $544,000 and $400,000, respectively, to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”), for working capital purposes. On December 2, 2022, the Company amended both
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TriSalus Life Sciences, Inc. amended a notes offering with MedTech Acquisition Sponsor LLC (effective 2022-12-02).
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- MedTech Acquisition Sponsor LLC
- Effective
- 2022-12-02
Exact text from the filing
On December 2, 2022, the Company amended both promissory notes to clarify that the principal of the notes will not be payable if the Company fails to complete its initial business combination on or before the 24 month anniversary of its initial public offering or such extended date as provided in the Company's amended and restated certificate of incorporation, as amended from time to time.
View on SEC.gov